Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $285K | $1.36M | $1.56M | $1.53M | $398K |
| Revenue growth | — | — | — | 378.2% | 14.3% | -1.5% | -74.1% |
| Operating income | -$16.5M | -$22.2M | -$43.6M | -$56.3M | -$67.1M | -$96.3M | -$31.0M |
| Operating margin | — | — | -15303.5% | -4131.0% | -4308.1% | -6280.8% | -7794.5% |
| Net income | -$16.3M | -$22.1M | -$43.5M | -$55.3M | -$62.7M | -$93.4M | -$28.9M |
| Net margin | — | — | -15267.7% | -4055.6% | -4023.1% | -6090.9% | -7266.1% |
| EPS (diluted) | -$82.23 | -$2.59 | -$3.35 | -$1.83 | -$1.26 | -$71.75 | -$18.62 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.8M | -$21.1M | -$25.8M | -$43.4M | -$63.3M | -$70.0M | -$28.9M |
| Capital expenditures | $211K | $1.77M | $3.38M | $164K | $1.05M | $2.34M | $116K |
| Free cash flow | -$14.0M | -$22.9M | -$29.2M | -$43.5M | -$64.4M | -$72.3M | -$29.0M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.81M | $74.6M | $45.7M | $32.5M | $22.4M | $40.6M | $15.9M |
| Total assets | $15.0M | $80.8M | $54.9M | $110M | $143M | $66.3M | $36.1M |
| Total liabilities | $7.63M | $6.34M | $20.6M | $29.2M | $53.2M | $54.8M | $46.8M |
| Shareholders' equity | -$123M | $74.5M | $34.3M | $80.8M | $89.4M | $11.6M | -$10.7M |
| Retained earnings | -$128M | -$150M | -$193M | -$249M | -$311M | -$405M | -$434M |
| Shares (wtd avg diluted) | 231K | 12.9M | 13.0M | 30.2M | 49.8M | 1.30M | 1.55M |
Every figure is extracted from Lyra Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.